In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor Pharmacy PracticeMidwestern University College of Pharmacy, Downers Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, IllinoisJonah Musa, MBBS, MSCI, PhDProfessor, Obstetrics and GynecologyUniversity of JosHonorary Consultant Obstetrician and GynecologistJos University Teaching HospitalJos, NigeriaContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3GRxpGQLink to full program:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related